Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Oct 2017

Driessler Frank, Miguelino Maricel G, Pierce Glenn F, Peters Robert T, Sommer Jurg M

Abstract excerpt

: The aim of this study was to compare the hemostatic efficacy of recombinant factor VIII Fc (rFVIIIFc) (Eloctate) and Advate by ex-vivo rotation thromboelastometry (ROTEM) of whole blood and to explore potential ROTEM parameters that may be more predictive of a patient's bleeding tendency than plasma FVIII activity. Thirteen clinical sites were selected to perform ROTEM on freshly collected blood samples from 44...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor VIII
Share to Immunoglobulin Fc Fragments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Recombinant Fusion Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28486277
DOI: 10.1097/MBC.0000000000000638
PMCID: PMC5642334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.PMID 28486277Read ↗

Hemostatic Profiling of Generic Factor Xa Inhibitors Using ROTEM® Viscoelastometry and Multimodal Coagulation Assays: A Real-World Study in a Tunisian CohortSemantic proximity Read ↗

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialSemantic proximity Read ↗

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ASemantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography.Semantic proximity Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

In vitro evaluation of global coagulation potential in the copresence of emicizumab and warfarin in whole blood using rotational thromboelastometrySemantic proximity Read ↗

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.Semantic proximity Read ↗

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.Semantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.